Mid-term results of percutaneous ventricular septal defect closure with Amplatzer Duct Occluder-II in children

Pamukçu, Özge; Narın, Nazmi; Baykan, Ali; Sunkak, Süleyman; Taşçı, Onur; Üzüm, Kazım

doi:10.1017/s104795111700107x

Cited by 19 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 However, the implantation of a foreign body in the heart raises the possibility of heart block, valve problems, and occluder migration. 9 Clinicians have certain doubts regarding transcatheter ventricular septal defect closure.…”

Section: Discussionmentioning

confidence: 99%

“…According to a review by Butera et al, the total number of percutaneous closures of ventricular septal defect in United States of America and European countries was less than 1000 cases. 9 Compared with the United States of America and with European countries, China has a more open attitude towards the transcatheter closure of ventricular septal defect; Thus, the implementation of transcatheter closure occurred earlier and more widely in China than in other nations due to concerns of cardiopulmonary bypass risk and to cosmetic concerns related to the incision used in traditional surgery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Aortic regurgitation after closure of ventricular septal defect by transcatheter device: the long-term complication

Han

Zhu

et al. 2020

Cardiol Young

View full text Add to dashboard Cite

Ventricular septal defect is the most common type of CHD, and transcatheter ventricular septal defect closure has been shown to be an alternative to surgical closure with acceptable mortality and morbidity as well as encouraging results. Short-term and mid-term follow-ups have indicated the safety and efficacy of transcatheter closure, but long-term follow-up results were rare. In this report, we first found that aortic regurgitation occurred in patients 9–12 years following transcatheter closure and regurgitation were gradually increased. The findings indicate that the long-term outcome of transcatheter closure of ventricular septal defect may not be as satisfied as expected.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Aortic regurgitation after closure of ventricular septal defect by transcatheter device: the long-term complication

Han

Zhu

et al. 2020

Cardiol Young

View full text Add to dashboard Cite

show abstract

“…Base on the technical issues of sheath size, possibility for implantation success, and complications, ADO II devices have been especially used in smaller children [19]. Moreover, the VSD occluder required a longer follow-up time in contrast to the more flexible and "off-label" used ADO II, thus, probable reasons for the higher closure rates observed for these devices [5,6,8,13,23,26,[28][29][30].…”

Section: Residual Shuntmentioning

confidence: 99%

Short- and Long-term Outcome After Interventional VSD Closure: A Single-Center Experience in Pediatric and Adult Patients

et al. 2020

View full text Add to dashboard Cite

Interventional closure of congenital ventricular septal defects (VSD) is recording a continuous rise in acceptance. Complete atrioventricular block (cAVB) and residual shunting are major concerns during follow-up, but long-term data for both are still limited. We retrospectively evaluated the outcome of patients with interventional VSD closure and focused on long-term results (> 1 year follow-up). Transcatheter VSD closures were performed between 1993 and 2015, in 149 patients requiring 155 procedures (104 perimembranous, 29 muscular, 19 residual post-surgical VSDs, and 3 with multiple defects). The following devices were used: 65 × Amplatzer™ Membranous VSD Occluder, 33 × Duct Occluder II, 27 × Muscular VSD Occluder, 3 × Duct Occluder I, 24 × PFM-Nit-Occlud®, and 3 × Rashkind-Occluder. The median age at time of implantation was 6.2 (0.01–66.1) years, median height 117 (49–188) cm, and median weight 20.9 (3.2–117) kg. Median follow-up time was 6.2 (1.1–21.3) years and closure rate was 86.2% at last follow-up. Complications resulting in device explantation include one case of cAVB with a Membranous VSD occluder 7 days after implantation and four cases due to residual shunt/malposition. Six (4%) deaths occurred during follow-up with only one procedural related death from a hybrid VSD closure. Overall, our reported results of interventional VSD closure show favorable outcomes with only one (0.7%) episode of cAVB. Interventional closure offers a good alternative to surgical closure and shows improved performance by using softer devices. However, prospective long-term data in the current era with different devices are still mandatory to assess the effectiveness and safety of this procedure.

show abstract

“…Afterwards, other cardiologists followed his lead and used Rashkind’s double-disc patent ductus arteriosus (PDA) umbrella, Rashkind’s ASD double-umbrella, and clamshell devices for transcatheter occlusion of VSDs 21 – 26 . Subsequently, other devices were used to percutaneously occlude the VSDs: buttoned device (Custom Medical Devices, Amarillo, TX, USA) 27 , 28 , CardioSEAL and STARFlex devices (Nitinol Medical Technologies, Inc., Boston, MA, USA) 29 , Nit-Occlud device (pfm - Produkte für die Medizin AG, Köln, Germany) 30 – 33 , Amplatzer Muscular VSD Occluder device (St. Jude Medical, Inc., St. Paul, MN, USA) 34 – 39 , detachable steel coils (Cook, Bloomington, IN, USA) 40 , Gianturco coils (Cook) 41 , flipper, 0.052ʺ Gianturco, or 0.035ʺ platinum coils (Cook) 42 , wireless devices such as detachable balloon and transcatheter patch (Custom Medical Devices) 43 , Amplatzer Duct Occluder (St. Jude Medical, Inc.) 44 , Shanghai symmetrical perimembranous VSD occluder (Shape Memory Alloy Ltd., Shanghai, China) 45 , Amplatzer Duct Occluder II (St. Jude Medical, Inc.) 46 – 56 , Cera devices (Lifetech Scientific Co. Ltd., Shenzhen, China) 57 , and perhaps other devices (not known to the authors).…”

Section: Ventricular Septal Defectsmentioning

confidence: 99%

“…Although CardioSEAL Septal Occlusion System with QwikLoad and the STARFlex Septal Occlusion System have received FDA approval in the past, they are not widely used at present. Free and detachable Gianturco coils 41 , 42 , Nit-Occlud device 30 – 33 , 75 , Amplatzer Duct Occluder 44 , and Amplatzer Duct Occluder II 46 – 56 are also being used on an off-label basis. Discussion of devices used on an off-label basis will not be included in this review; the interested reader may review the respective publications 30 – 33 , 41 , 42 , 44 , 46 – 56 , 75 .…”

Section: Ventricular Septal Defectsmentioning

confidence: 99%

Recent advances in managing septal defects: ventricular septal defects and atrioventricular septal defects

Rao

Harris

2018

F1000Res

View full text Add to dashboard Cite

This review discusses the management of ventricular septal defects (VSDs) and atrioventricular septal defects (AVSDs). There are several types of VSDs: perimembranous, supracristal, atrioventricular septal, and muscular. The indications for closure are moderate to large VSDs with enlarged left atrium and left ventricle or elevated pulmonary artery pressure (or both) and a pulmonary-to-systemic flow ratio greater than 2:1. Surgical closure is recommended for large perimembranous VSDs, supracristal VSDs, and VSDs with aortic valve prolapse. Large muscular VSDs may be closed by percutaneous techniques. A large number of devices have been used in the past for VSD occlusion, but currently Amplatzer Muscular VSD Occluder is the only device approved by the US Food and Drug Administration for clinical use. A hybrid approach may be used for large muscular VSDs in small babies. Timely intervention to prevent pulmonary vascular obstructive disease (PVOD) is germane in the management of these babies. There are several types of AVSDs: partial, transitional, intermediate, and complete. Complete AVSDs are also classified as balanced and unbalanced. All intermediate and complete balanced AVSDs require surgical correction, and early repair is needed to prevent the onset of PVOD. Surgical correction with closure of atrial septal defect and VSD, along with repair and reconstruction of atrioventricular valves, is recommended. Palliative pulmonary artery banding may be considered in babies weighing less than 5 kg and those with significant co-morbidities. The management of unbalanced AVSDs is more complex, and staged single-ventricle palliation is the common management strategy. However, recent data suggest that achieving two-ventricle repair may be a better option in patients with suitable anatomy, particularly in patients in whom outcomes of single-ventricle palliation are less than optimal. The majority of treatment modes in the management of VSDs and AVSDs are safe and effective and prevent the development of PVOD and cardiac dysfunction.

show abstract

Mid-term results of percutaneous ventricular septal defect closure with Amplatzer Duct Occluder-II in children

Cited by 19 publications

References 16 publications

Aortic regurgitation after closure of ventricular septal defect by transcatheter device: the long-term complication

Aortic regurgitation after closure of ventricular septal defect by transcatheter device: the long-term complication

Short- and Long-term Outcome After Interventional VSD Closure: A Single-Center Experience in Pediatric and Adult Patients

Recent advances in managing septal defects: ventricular septal defects and atrioventricular septal defects

Contact Info

Product

Resources

About